LUMO Lumos Pharma Inc.

10.01
-1.15  -10%
Previous Close 11.16
Open 11.16
52 Week Low 7.232
52 Week High 36.72
Market Cap $83,657,484
Shares 8,357,391
Float 6,336,966
Enterprise Value $-13,709,517
Volume 53,980
Av. Daily Volume 79,716
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
LUM-201 (OraGrowtH210)
Pediatric Growth Hormone Deficiency (PGHD)
Phase 2
Phase 2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
LUM-201 (OraGrowtH212)
Pediatric Growth Hormone Deficiency (PGHD)
Phase 2
Phase 2
Phase 2 PK/PD trial is open for enrollment - June 28, 2021.
ERVEBO (V920)
Ebola
Approved
Approved
FDA Approval announced December 19, 2019.

Latest News

  1. AUSTIN, Texas, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 23rd Annual Global Investment Conference and the Cantor Virtual Global Healthcare Conference in September.

    Event:H.C. Wainwright 23rd Annual Global Investor Conference – September 13-15
    Presentation:Pre-recorded presentation available beginning September 13 at 7:00 AM (ET)
    Webcast link:Here
    Event:Cantor Virtual Global Healthcare Conference – September 27-30
    Presentation:Live fireside chat September 29 from 4:00-4:30 PM (ET)
    Webcast link:Here

    The webcasts for each presentation can also be found on the Company's website…

    AUSTIN, Texas, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 23rd Annual Global Investment Conference and the Cantor Virtual Global Healthcare Conference in September.

    Event:H.C. Wainwright 23rd Annual Global Investor Conference – September 13-15
    Presentation:Pre-recorded presentation available beginning September 13 at 7:00 AM (ET)
    Webcast link:Here
    Event:Cantor Virtual Global Healthcare Conference – September 27-30
    Presentation:Live fireside chat September 29 from 4:00-4:30 PM (ET)
    Webcast link:Here

    The webcasts for each presentation can also be found on the Company's website under "Events & Presentations" in the Investors & Media section where a replay of each presentation will be also be available. Please contact your H.C. Wainwright or Cantor salesperson, or Lumos Pharma Investor Relations, to schedule one-on-one meetings with the management team during the conferences or thereafter.

    About Lumos Pharma

    Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma's lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, and a PK/PD trial, the OraGrowtH212 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

    Investor & Media Contact:

    Lisa Miller

    Lumos Pharma Investor Relations

    512-792-5454

    ir@lumos-pharma.com

    Source: Lumos Pharma, Inc.



    Primary Logo

    View Full Article Hide Full Article
  2. Lumos Pharma strengthens leadership team with promotion of John McKew, PhD to President, and addition of David B. Karpf, MD as Chief Medical Officer and Mark Bach, MD, PhD to Advisory Board

    • Screening and enrollment of OraGrowtH210 and OraGrowtH212 Trials progress

    AUSTIN, Texas, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the second quarter ending June 30, 2021 and provided an update on clinical and corporate activities.

    "The enhancement of Lumos Pharma's leadership team and encouraging recent trends in screening and enrollment for both OraGrowtH210 and OraGrowtH212 Trials are exciting developments…

    Lumos Pharma strengthens leadership team with promotion of John McKew, PhD to President, and addition of David B. Karpf, MD as Chief Medical Officer and Mark Bach, MD, PhD to Advisory Board

    • Screening and enrollment of OraGrowtH210 and OraGrowtH212 Trials progress

    AUSTIN, Texas, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the second quarter ending June 30, 2021 and provided an update on clinical and corporate activities.

    "The enhancement of Lumos Pharma's leadership team and encouraging recent trends in screening and enrollment for both OraGrowtH210 and OraGrowtH212 Trials are exciting developments for the Company," commented Rick Hawkins, Chairman and CEO of Lumos Pharma. "John McKew, David Karpf, and Mark Bach each bring significant clinical development and management expertise to their new roles with the Company, strengthening our ability to execute on our clinical and corporate strategy. The majority of our trial sites are now open, and we continue to work to bring the remainder online. Additionally, as children return to school this fall and regular pediatrician visits resume, we believe these factors should lead to increased referrals and an acceleration of enrollment in our trials."  

    Corporate Update:

    John McKew, PhD, Chief Operating Officer & Chief Scientific Officer, Promoted to President

    Our Chief Operating Officer and Chief Scientific Officer, John McKew, was recently promoted to President of Lumos Pharma effective August 1, 2021 as part of a planned succession process. Dr. McKew has nearly 30 years of experience developing novel therapeutics during which he successfully advanced multiple therapies through preclinical and into clinical development, both at the NIH and in the pharmaceutical industry. Dr. McKew has served as Chief Operating Officer of Lumos Pharma since April 2020 and as Chief Scientific Officer since he joined the Company in 2016.  

    David B. Karpf, MD, Experienced Endocrinologist and Pharma Executive, Named Chief Medical Officer

    Pharma industry veteran and academician, David B. Karpf, MD, joined Lumos Pharma as Chief Medical Officer on August 3, 2021. Dr. Karpf is an Adjunct Clinical Professor in the Division of Endocrinology at Stanford University School of Medicine with over 35 years of expertise in all aspects of clinical endocrinology. He is also an accomplished executive with 30 years of experience in the development of biopharmaceuticals and small molecular weight drugs in the areas of endocrinology and rare diseases, among others. Most recently, Dr. Karpf served as Vice President, Clinical Development for Ascendis Pharma where he was responsible for several compounds in clinical development, including TransCon GH, long-acting growth hormone for once weekly treatment of growth hormone deficiency, and TransCon PTH. Dr. Karpf has held leadership positions at several biopharmaceutical and pharma companies, including Merck where he originally gained experience with Lumos Pharma's oral growth hormone secretagogue, LUM-201.  

    Pediatric Endocrinologist and Biopharma Executive, Mark Bach, MD, PhD, Joins Advisory Board

    Mark Bach, MD, PhD, pediatric endocrinologist and seasoned pharmaceutical executive, joined Lumos Pharma's Clinical Scientific Advisory Board on July 15, 2021. Dr. Bach is currently the Chief Medical Officer for ShouTi Inc., having recently joined from Ascendis Pharma where he served as Senior Vice President, Endocrine Medical Sciences. Dr. Bach is a pediatric endocrinologist with 30 years of clinical research and pharmaceutical development experience. Prior to Ascendis, Dr. Bach held successive leadership roles in research and development at both Johnson & Johnson and Merck. While at Merck, he conducted extensive clinical and preclinical research on growth hormone, IGF-1 and LUM-201 (MK-0677).

    Clinical Update:

    OraGrowtH210 Trial of LUM-201 in PGHD

    As the Company announced on July 21, 2021, given the slower pace of site initiation and enrollment of the Phase 2 OraGrowtH210 Trial of LUM-201 in PGHD primarily due to the impact of COVID, the 6-month primary outcome data for OraGrowtH210 is now anticipated in the second half of 2023. The treatment period for this trial has been extended to 12 months to capture additional data for future regulatory filings and to meet FDA requirements to initiate our proposed 3-year long-term extension study, the OraGrowtH211 Trial. We do not anticipate these protocol changes, on a stand-alone basis, to extend the time to initiation of our Phase 3 clinical trial. The primary outcome for the Phase 2 OraGrowtH210 Trial continues to be the preliminary validity of our Predictive Enrichment Marker (PEM) strategy with the goal of selecting the optimal dose for a pivotal Phase 3 study in PGHD.

    PK/PD OraGrowtH212 Trial of LUM-201 in PGHD Initiated Q2 2021  

    The OraGrowtH212 Trial was initiated in June and is currently enrolling patients.   This study will evaluate the PK/PD effects of LUM-201 in PGHD patients at two dose levels, 1.6 and 3.2 mg/kg/day, to confirm prior clinical data illustrating the increased pulsatile release of endogenous growth hormone unique to LUM-201 and its potential for this mechanism of action to contribute to efficacy in PGHD. This open-label trial will be extended from six months to twelve months to capture additional PK/PD and height velocity data. The PD pulsatility assessment will continue to occur at six months on therapy as planned.

    Pipeline Expansion

    We have been conducting an assessment of the range of disease areas where LUM-201 would have medical utility for purposes of prioritizing our next indication and longer-term life cycle planning. These assessments reinforce our conviction that LUM-201 represents a pipeline-in-a-product and look forward to advancing the next phase of LUM-201 opportunities. In addition, with a heightened sensitivity toward value creation, we continue to evaluate select rare disease assets under consideration to add to our product portfolio.  

    Financial Results for the Quarter Ended June 30, 2021

    • Cash Position – Lumos Pharma ended the second quarter on June 30, 2021, with cash and cash equivalents totaling $107.7 million compared to $98.7 million on December 31, 2020. Cash on hand as of the end of Q2 2021 is expected to support operations through the primary outcome data readout from OraGrowtH210 Trial in the second half of 2023 and the OraGrowtH212 Trial.  
    • R&D Expenses – Research and development expenses were $4.1 million, an increase of $1.4 million for the three months ended June 30, 2021 compared to the same period in 2020, primarily due to increases of $1.8 million in clinical trial and contract manufacturing expenses, offset by a decrease of $0.4 million in personnel-related and operating expenses for insurance, rent, supplies and depreciation.
    • G&A Expenses – General and administrative expenses were $4.6 million, an increase of $0.4 million for the three months ended June 30, 2021, compared to the same period in 2020, primarily due to increases of $0.6 million in personnel-related expenses, of which $0.9 million relates to severance expense recorded for the departure of our former CFO, Carl W. Langren on June 30, 2021 and $0.5 million in stock compensation expenses, of which $0.4 million relates to the accelerated vesting of all non-vested equity awards held by Mr. Langren upon his departure. These increases were offset by a $0.4 million decrease in legal and consulting expenses and a $0.3 million reduction in operating expenses for insurance, rent, supplies, and depreciation.
    • Net Loss – The net loss for the second quarter ended June 30, 2021 was $8.7 million compared to net loss of $5.4 million for the same period in 2020.
    • Lumos Pharma ended Q2 2021 with 8,357,391 shares outstanding.  

    Conference Call and Webcast Details

    The Company has scheduled a conference call and webcast for 11:00 a.m. ET today to discuss its financial results and to give an update on clinical and business development activities. There will also be a question-and-answer session following management's prepared remarks.

    Access to the live conference call is available five minutes prior to the start of the call by dialing (855) 469-0612 (U.S.) or (484) 756-4268 (international). The conference call will be webcast live and a link to the webcast can be accessed through the Lumos Pharma website at https://lumos-pharma.com/ in the "Investors & Media" section under "Events and Presentations" or through this link: https://edge.media-server.com/mmc/p/kfnwndzq. To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.   A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and using the passcode 8050625. The replay will be available for two weeks from the date of the call.

    About Lumos Pharma

    Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma's lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, and a PK/PD trial, the OraGrowtH212 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements of Lumos Pharma, Inc. (the "Company") that involve substantial risks and uncertainties. All such statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "forecast," "projected," "guidance," "upcoming," "will," "would," "plan," "intend," "anticipate," "approximate," "expect," "potential," "imminent," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, encouraging recent trends in screening and enrollment for both OraGrowtH210 and OraGrowtH212 Trials, that as children return to school this fall and regular pediatrician visits resume, we believe these factors should lead to increased referrals and an acceleration of enrollment in our trials, that the 6-month primary outcome data for OraGrowtH210 is now anticipated in the second half of 2023, that we do not anticipate these protocol changes, on a stand-alone basis, to extend the time to initiation of our Phase 3 clinical trial, our conviction that LUM-201 represents a pipeline-in-a-product and look forward to advancing the next phase of LUM-201 opportunities, that   cash on hand as of the end of Q2 2021 is expected to support operations through the primary outcome data readout from OraGrowtH210 Trial in the second half of 2023 and the OraGrowtH212 Trial, the ability of prior research results to forecast the performance of therapeutic agents in the clinic, anticipated business development activities, anticipated market reception to our treatment regimen for PGHD and other indications, plans related to initiation and execution of clinical trials; plans related to moving additional indications into clinical development; future financial performance, results of operations, cash position and sufficiency of capital resources to fund its operating requirements; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes due to a number of important factors, including the effects of pandemics or other widespread health problems, the outcome of our future interactions with regulatory authorities, our ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the ability to obtain the necessary patient enrollment for our product candidate in a timely manner, the ability to successfully develop our product candidate, the timing and ability of Lumos to raise additional equity capital as needed and other risks that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements as discussed in "Risk Factors" and elsewhere in Lumos Pharma's Annual Report on Form 10-K for the year ended December 31, 2020 and other reports filed with the SEC. The forward-looking statements in this press release represent the Company's views as of the date of this press release. The Company anticipates that subsequent events and developments will cause their views to change. However, while it may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing the Company's views as of any date subsequent to the date of this press release.

    Investor & Media Contact:

    Lisa Miller

    Lumos Pharma Investor Relations

    512-792-5454

    ir@lumos-pharma.com

    Lumos Pharma, Inc.
    Condensed Consolidated Statements of Operations
    (unaudited)
    (In thousands, except share and per share amounts)



            
     Three Months Ended June 30, Six Months Ended June 30,
     2021 2020 2021 2020
    Revenues:       
    Licensing and collaboration revenue10  33  10  55 
    Total revenues10  33  10  55 
    Operating expenses:       
    Research and development4,113  2,763  8,773  4,669 
    General and administrative4,561  4,147  8,518  7,478 
    Total operating expenses8,674  6,910  17,291  12,147 
    Loss from operations(8,664) (6,877) (17,281) (12,092)
    Other income and expense:       
    Other income (expense), net(8) 24  12  161 
    Interest income2  74  5  79 
    Interest expense    (37) (50)
    Other (expense) income, net(6) 98  (20) 190 
    Net loss before taxes(8,670) (6,779) (17,301) (11,902)
    Income tax benefit  1,426    6,889 
    Net loss$(8,670) $(5,353) $(17,301) $(5,013)
    Accretion of preferred stock to current redemption value    $  (651)
    Net loss attributable to common shareholders$(8,670) $(5,353) $(17,301) $(5,664)
            
    Net loss per share of common stock       
    Basic and diluted$(1.04) $(0.65) $(2.11) $(1.08)
            
    Weighted average number of common shares outstanding       
    Basic and diluted8,345,023  8,292,809  8,199,869  5,243,577 



    Lumos Pharma, Inc.
    Condensed Consolidated Balance Sheets
    (unaudited)
    (In thousands, except share and per share amounts)



      June 30, December 31,
      2021 2020
    Assets    
    Current assets:    
    Cash and cash equivalents $107,696  $98,679 
    Prepaid expenses and other current assets 5,655  3,506 
    Income tax receivable 116  115 
    Other receivables 9  26,149 
    Total current assets 113,476  128,449 
    Non-current assets:    
    Property and equipment, net 79  335 
    Right-of-use asset 714  249 
    Total non-current assets 793  584 
    Total assets $114,269  $129,033 
    Liabilities and Stockholders' Equity     
    Current liabilities:    
    Accounts payable $312  $244 
    Accrued expenses 6,117  5,898 
    Current portion of lease liability 348  319 
    Total current liabilities 6,777  6,461 
    Long-term liabilities:    
    Royalty obligation payable to Iowa Economic Development Authority 6,000  6,000 
    Lease liability 370   
    Total long-term liabilities 6,370  6,000 
    Total liabilities 13,147  12,461 
    Commitments and contingencies:    
    Stockholders' equity:    
    Undesignated preferred stock, $— par value: Authorized shares - 5,000,000 at June 30, 2021 and December 31, 2020; issued and outstanding shares - 0 at June 30, 2021 and December 31, 2020 $  $ 
    Common stock, $0.01 par value: Authorized shares - 75,000,000 at June 30, 2021 and December 31, 2020; issued 8,366,819 and 8,305,269 at June 30, 2021 and December 31, 2020, respectively and outstanding 8,357,391 and 8,305,269 at June 30, 2021 and December 31, 2020, respectively $83  $83 
    Treasury stock, at cost, 9,428 and 0 at June 30, 2021 and December 31, 2020, respectively $(114) $ 
    Additional paid-in capital $184,445  $182,480 
    Accumulated deficit $(83,292) $(65,991)
    Total stockholders' equity 101,122  116,572 
    Total liabilities and stockholders' equity $114,269  $129,033 
         


    Primary Logo

    View Full Article Hide Full Article
  3. AUSTIN, Texas, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that experienced endocrinologist and pharma executive, David B. Karpf, MD, joined the Company August 3, 2021 as its new Chief Medical Officer.

    "I am thrilled to welcome noted endocrinologist and industry veteran, Dr. David B. Karpf, as our new Chief Medical Officer," commented Rick Hawkins, Chairman and CEO of Lumos Pharma. "Dr. Karpf's experience in both the growth hormone space and in the advancement of therapeutic candidates through clinical development will add invaluable expertise to Lumos Pharma's clinical team."

    David B. Karpf, MD is an academically trained…

    AUSTIN, Texas, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that experienced endocrinologist and pharma executive, David B. Karpf, MD, joined the Company August 3, 2021 as its new Chief Medical Officer.

    "I am thrilled to welcome noted endocrinologist and industry veteran, Dr. David B. Karpf, as our new Chief Medical Officer," commented Rick Hawkins, Chairman and CEO of Lumos Pharma. "Dr. Karpf's experience in both the growth hormone space and in the advancement of therapeutic candidates through clinical development will add invaluable expertise to Lumos Pharma's clinical team."

    David B. Karpf, MD is an academically trained endocrinologist with over 35 years of expertise in all aspects of clinical endocrinology. He is also an accomplished biopharmaceutical executive with 30 years of experience in the development of biopharmaceuticals and small molecular weight drugs in the areas of endocrinology, rare diseases, and autoimmune disease, among others. Dr. Karpf's extensive experience spans all facets of biopharmaceutical clinical development from preclinical to Phase 4 – including successful interactions with US and international regulatory agencies, and marketing/launch activities – and he has contributed substantially to 6 NDAs.

    Dr. Karpf is an Adjunct Clinical Professor in the Division of Endocrinology at Stanford University School of Medicine, where he has followed approximately 1600 patients in an endocrinology sub-specialty clinic since 1997. Most recently, Dr. Karpf served as Vice President, Clinical Development for Ascendis Pharma. There he was responsible for several compounds in clinical development, including TransCon GH, long-acting growth hormone for once weekly treatment of growth hormone deficiency in children. Dr. Karpf previously served as Chief Medical Officer at both Virobay Inc. and Metabolex, Inc. and has held leadership positions in regulatory affairs at other biopharmaceutical companies. Earlier in his career, Dr. Karpf served in leadership positions in clinical research in endocrinology at Merck where he originally gained experience with Lumos Pharma's oral growth hormone secretagogue, LUM-201.

    Dr. Karpf received his AB from University of California, Berkley and his MD from University of California, San Diego. He completed both his internal medicine residency and fellowship in Endocrinology, Diabetes & Metabolism at UCLA School of Medicine/Cedars-Sinai Medical Center and completed a post-fellowship program in metabolic bone disease at UCSF School of Medicine.

    "I am delighted to join the Lumos Pharma team at this juncture as the Company advances its novel oral therapeutic candidate, LUM-201, for pediatric growth hormone deficiency," stated Dr. Karpf. "While at Merck, I became familiar with LUM-201 and the encouraging clinical data supporting this molecule. I am enthusiastic to assist Lumos Pharma in revealing the potential LUM-201 holds in PGHD and in other indications currently treated by injectable therapeutics."

    About Lumos Pharma

    Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma's lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, and a PK/PD trial, the OraGrowtH212 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements of Lumos Pharma, Inc. (the "Company") that involve substantial risks and uncertainties. All such statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "forecast," "projected," "guidance," "upcoming," "will," "would," "plan," "intend," "anticipate," "approximate," "expect," "potential," "imminent," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, the ability of prior research results to forecast the performance of therapeutic agents in the clinic, anticipated market reception to our treatment regimen for PGHD and other indications, plans related to initiation and execution of clinical trials; plans related to moving additional indications into clinical development; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes due to a number of important factors, including the effects of pandemics or other widespread health problems, the outcome of our future interactions with regulatory authorities, our ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the ability to obtain the necessary patient enrollment for our product candidate in a timely manner, the ability to successfully develop our product candidate, the timing and ability of Lumos to raise additional equity capital as needed and other risks that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements as discussed in "Risk Factors" and elsewhere in Lumos Pharma's Annual Report on Form 10-K for the year ended December 31, 2020 and other reports filed with the SEC. The forward-looking statements in this press release represent the Company's views as of the date of this press release. The Company anticipates that subsequent events and developments will cause their views to change. However, while it may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing the Company's views as of any date subsequent to the date of this press release.

    Investor & Media Contact:

    Lisa Miller

    Lumos Pharma Investor Relations

    512-792-5454

    ir@lumos-pharma.com



    Primary Logo

    View Full Article Hide Full Article
  4. AUSTIN, Texas, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that current Chief Operating Officer and Chief Scientific Officer, John McKew, PhD, was promoted to President of Lumos Pharma effective August 1, 2021 as part of the Company's planned succession.

    "I am excited to announce the promotion of John to President as part of the Lumos Pharma succession planning undergone by the Company and our Board of Directors," commented Rick Hawkins, Chairman and CEO of Lumos Pharma. "I have worked with John for nearly ten years at both Lumos and, prior to that, in a collaboration during his tenure at the NIH. Our interactions over…

    AUSTIN, Texas, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that current Chief Operating Officer and Chief Scientific Officer, John McKew, PhD, was promoted to President of Lumos Pharma effective August 1, 2021 as part of the Company's planned succession.

    "I am excited to announce the promotion of John to President as part of the Lumos Pharma succession planning undergone by the Company and our Board of Directors," commented Rick Hawkins, Chairman and CEO of Lumos Pharma. "I have worked with John for nearly ten years at both Lumos and, prior to that, in a collaboration during his tenure at the NIH. Our interactions over this period and John's contributions as COO and Chief Scientific Officer at Lumos Pharma support our decision to turn over more responsibility to him. John has proven to be an outstanding leader, and this promotion is a testament to that and to his unwavering commitment to the Company"

    John McKew, PhD has nearly 30 years of experience developing novel therapeutics during which he successfully advanced multiple therapies through preclinical and into clinical development. At Lumos Pharma, Dr. McKew has served as Chief Operating Officer since April 2020 and as Chief Scientific Officer since he joined the company in 2016. In these positions, he has helped identify clinical and commercial opportunities for Lumos Pharma and has played a key role in the development and implementation of the Company's clinical and corporate strategy to support a successful path to commercialization and value creation.

    Prior to Lumos Pharma, Dr. McKew served as Vice President of Research at aTyr Pharma where he led a research team discovering and advancing protein-based therapeutics for rare diseases. He has also served as Acting Scientific Director for the National Center for Advancing Translational Science (NCATS) intramural group, a part of the National Institute of Health (NIH). At NCATS, his lab's work on rare diseases and public/private partnerships led to the collaborative advancement of several therapeutic candidates currently being commercialized by pharmaceutical companies. Prior to his position at the NIH, Dr. McKew held a Director level position at Wyeth Research, after beginning his career at Genetics Institute, Inc., before the two companies merged.

    Beyond his work with Lumos Pharma, Dr. McKew is currently an Adjunct Professor at the Boston University School of Medicine and has previously served as the Chair Elect, Chair, and Immediate Past Chair of the American Chemical Society's Northeastern section. Dr. McKew also serves on multiple translational review panels at the NIH and other funding agencies. He has over 70 peer-reviewed publications and granted patents. Dr. McKew graduated from State University of New York at Stony Brook with B.S. degrees in Chemistry and Biochemistry He completed his Ph.D. in Organic Chemistry at University of California, Davis and held post-doctoral research positions at the University of Geneva and Firmenich, SA.

    "I am honored to accept the position of President of Lumos Pharma," John McKew stated, "and look forward to continuing my work with Rick and the entire team to advance our current LUM-201 program for children with growth hormone deficiency and execute on our clinical and corporate goals."

    About Lumos Pharma

    Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma's lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, and a PK/PD trial, the OraGrowtH212 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements of Lumos Pharma, Inc. (the "Company") that involve substantial risks and uncertainties. All such statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "forecast," "projected," "guidance," "upcoming," "will," "would," "plan," "intend," "anticipate," "approximate," "expect," "potential," "imminent," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, anticipated market reception to our treatment regimen for PGHD and other indications, plans related to initiation and execution of clinical trials, and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes due to a number of important factors, including the effects of pandemics or other widespread health problems, the outcome of our future interactions with regulatory authorities, the ability to obtain the necessary patient enrollment for our product candidate in a timely manner, the ability to successfully develop our product candidate and other risks that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements as discussed in "Risk Factors" and elsewhere in Lumos Pharma's Annual Report on Form 10-K for the year ended December 31, 2020 and other reports filed with the SEC. The forward-looking statements in this press release represent the Company's views as of the date of this press release. The Company anticipates that subsequent events and developments will cause their views to change. However, while it may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing the Company's views as of any date subsequent to the date of this press release.

    Investor & Media Contact:

    Lisa Miller

    Lumos Pharma Investor Relations

    512-792-5454

    ir@lumos-pharma.com



    Primary Logo

    View Full Article Hide Full Article
  5. AUSTIN, Texas, July 26, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Mark Bach, M.D., Ph.D., accepted his appointment to the Company's Clinical Scientific Advisory Board (CSAB) effective July 15, 2021. Dr. Bach joins the Company's accomplished advisory board comprised of noted pediatric endocrinologists, Peter Clayton, M.D., Ph.D.; Reiko Horikawa, M.D., Ph.D.; George Werther, M.D., Ph.D.; and Chairman, Ron Rosenfeld, M.D.

    Dr. Bach is currently the Chief Medical Officer for ShouTi Inc., having recently joined from Ascendis Pharma where he served as Senior Vice President, Endocrine Medical Sciences. Dr. Bach is a pediatric endocrinologist…

    AUSTIN, Texas, July 26, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Mark Bach, M.D., Ph.D., accepted his appointment to the Company's Clinical Scientific Advisory Board (CSAB) effective July 15, 2021. Dr. Bach joins the Company's accomplished advisory board comprised of noted pediatric endocrinologists, Peter Clayton, M.D., Ph.D.; Reiko Horikawa, M.D., Ph.D.; George Werther, M.D., Ph.D.; and Chairman, Ron Rosenfeld, M.D.

    Dr. Bach is currently the Chief Medical Officer for ShouTi Inc., having recently joined from Ascendis Pharma where he served as Senior Vice President, Endocrine Medical Sciences. Dr. Bach is a pediatric endocrinologist with 30 years of clinical research and pharmaceutical development experience, including extensive global experience building and leading clinical teams that have successfully launched innovative pharmaceutical products into worldwide markets. Prior to Ascendis, Dr. Bach spent nine years at Janssen, a subsidiary of Johnson & Johnson, where he held successive leadership roles in research and development, culminating in the position of Head of Asia Pacific Medical Sciences and Head of China R&D. Prior to Janssen, Dr. Bach held positions of increasing responsibility in Clinical Research at Merck & Co., Inc., ending his tenure there as Vice President of Clinical Research Operations Worldwide. Early in his career, Dr. Bach conducted extensive clinical and preclinical research on growth hormone, IGF-1 and LUM-201 (MK-0677), with data from this work published in scientific and medical journals.

    "Dr. Mark Bach brings to our advisory board a wealth of knowledge of, and experience with, growth hormone related disorders and a significant understanding of the unique advantages LUM-201 could offer to the growth hormone deficient population," said Rick Hawkins, CEO, President and Chairman of Lumos Pharma. "We are thrilled to have Dr. Bach join the other esteemed members of our CSAB and look forward to his contributions to Lumos Pharma's clinical and commercial strategy."

    "Children with growth hormone deficiency have had to endure growth hormone injections as the only treatment option for over thirty years," said Mark Bach. "Lumos Pharma's novel oral therapeutic candidate, LUM-201 could provide a welcome alternative for many of these children. Through my research at Merck, I saw firsthand the promising clinical data supporting LUM-201 and am excited to join fellow advisory board members to assist Lumos Pharma in advancing this compound and executing on its clinical strategy."

    Throughout his career, Dr. Bach has authored numerous publications, has lectured in national and international forums and has served on professional society advisory boards to advance the field of endocrinology and clinical research. Dr. Bach is an active member of The Endocrine Society and has served on several of this organization's committees. Dr. Bach received a B.A. in chemistry from Carleton College where he was awarded Phi Beta Kappa, received an M.D. from Baylor College of Medicine and a Ph.D. in pathology from The University of Chicago. Dr. Bach completed his pediatric residency at the Baylor College of Medicine and completed a pediatric endocrinology fellowship and post-doctoral research at the National Institute of Health, working in the laboratories of Drs. Derek LeRoith and Carolyn Bondy.

    About Lumos Pharma

    Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma's lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, and a PK/PD trial, the OraGrowtH212 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements of Lumos Pharma, Inc. (the "Company") that involve substantial risks and uncertainties. All such statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words "forecast," "projected," "guidance," "upcoming," "will," "would," "plan," "intend," "anticipate," "approximate," "expect," "potential," "imminent," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, the ability of prior research results to forecast the performance of therapeutic agents in the clinic, anticipated business development activities, anticipated market reception to our treatment regimen for PGHD and other indications, plans related to initiation and execution of clinical trials; plans related to moving additional indications into clinical development; future financial performance, results of operations, cash position and sufficiency of capital resources to fund its operating requirements; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes due to a number of important factors, including the effects of pandemics or other widespread health problems, the outcome of our future interactions with regulatory authorities, our ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the ability to obtain the necessary patient enrollment for our product candidate in a timely manner, the ability to successfully develop our product candidate, the timing and ability of Lumos to raise additional equity capital as needed and other risks that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements as discussed in "Risk Factors" and elsewhere in Lumos Pharma's Annual Report on Form 10-K for the year ended December 31, 2020 and other reports filed with the SEC. The forward-looking statements in this press release represent the Company's views as of the date of this press release. The Company anticipates that subsequent events and developments will cause their views to change. However, while it may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing the Company's views as of any date subsequent to the date of this press release.

    Investor & Media Contact:

    Lisa Miller

    Lumos Pharma Investor Relations

    512-792-5454

    ir@lumos-pharma.com



    Primary Logo

    View Full Article Hide Full Article
View All Lumos Pharma Inc. News